This site is intended for US Healthcare Professionals only.


Browse the library of publications below for the latest research from ADC Therapeutics scientists.

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia Jain N, et al. Blood Adv. Feb 2020.
CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy Thapa B, et al. Blood Adv. Aug 2020.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma Hamadani M, et al. Blood. May 2021.
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021.
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study Hamadani M, et al. Lancet Haematol. May 2021.

Contact ADC Therapeutics

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at